DE60218146D1 - Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung - Google Patents

Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung

Info

Publication number
DE60218146D1
DE60218146D1 DE60218146T DE60218146T DE60218146D1 DE 60218146 D1 DE60218146 D1 DE 60218146D1 DE 60218146 T DE60218146 T DE 60218146T DE 60218146 T DE60218146 T DE 60218146T DE 60218146 D1 DE60218146 D1 DE 60218146D1
Authority
DE
Germany
Prior art keywords
methods
treating
inflammatory component
brain disease
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60218146T
Other languages
English (en)
Other versions
DE60218146T9 (de
DE60218146T2 (de
Inventor
E Bolton
Arkady Mandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of DE60218146D1 publication Critical patent/DE60218146D1/de
Application granted granted Critical
Publication of DE60218146T2 publication Critical patent/DE60218146T2/de
Publication of DE60218146T9 publication Critical patent/DE60218146T9/de
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60218146T 2001-04-06 2002-04-08 Verfahren zur Behandlung der entzündlichen Komponente einer Hirnerkrankung Expired - Fee Related DE60218146T9 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28212001P 2001-04-06 2001-04-06
US282120P 2001-04-06
PCT/CA2002/000494 WO2002080945A2 (en) 2001-04-06 2002-04-08 Methods for treating the inflammatory component of a brain disorder

Publications (3)

Publication Number Publication Date
DE60218146D1 true DE60218146D1 (de) 2007-03-29
DE60218146T2 DE60218146T2 (de) 2007-11-22
DE60218146T9 DE60218146T9 (de) 2008-02-21

Family

ID=23080183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218146T Expired - Fee Related DE60218146T9 (de) 2001-04-06 2002-04-08 Verfahren zur Behandlung der entzündlichen Komponente einer Hirnerkrankung

Country Status (9)

Country Link
US (1) US7122208B2 (de)
EP (1) EP1379260B1 (de)
JP (1) JP2005508847A (de)
AT (1) ATE353659T1 (de)
AU (1) AU2002249034B2 (de)
CA (1) CA2442313A1 (de)
DE (1) DE60218146T9 (de)
ES (1) ES2282405T3 (de)
WO (1) WO2002080945A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
AU2003263962A1 (en) 2002-07-31 2004-02-16 Earl Y. Cheng Tissue compositions and methods for producing same
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
WO2008136958A1 (en) * 2007-04-30 2008-11-13 Opthera, Inc. Uva1-led phototherapy device and method
EP2442819A4 (de) * 2009-06-19 2013-01-02 Acquisci Inc Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon
CN102802643A (zh) * 2009-06-19 2012-11-28 阿奎赛公司 利用臭氧治疗炎性病症、心血管疾病和急性缺血性脑中风
US10357450B2 (en) 2012-04-06 2019-07-23 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
US10577554B2 (en) * 2013-03-15 2020-03-03 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
US11717698B1 (en) 2020-04-23 2023-08-08 Hugh McGrath, Jr. Therapy, treatment, and process for photodynamic inactivation of COVID-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
EP1243278B1 (de) * 1992-02-07 2007-01-03 Vasogen Ireland Limited Verwendung von Blut mit erhöhter Stickoxidkonzentration zur Herstellung eines Medikaments
NZ306395A (en) 1995-05-05 2000-02-28 Vasogen Inc Treatment of blood to remove symptoms of vascular disorders by elevation of temperature, ultraviolet radiation or treatment with an oxidative environment
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
DE60002979T2 (de) 1999-01-12 2004-05-19 Vasogen Ireland Ltd., Shannon Vorbehandlung gegen zelltot

Also Published As

Publication number Publication date
ES2282405T3 (es) 2007-10-16
US20020155098A1 (en) 2002-10-24
ATE353659T1 (de) 2007-03-15
AU2002249034B2 (en) 2007-08-02
DE60218146T9 (de) 2008-02-21
EP1379260A2 (de) 2004-01-14
CA2442313A1 (en) 2002-10-17
WO2002080945A2 (en) 2002-10-17
JP2005508847A (ja) 2005-04-07
EP1379260B1 (de) 2007-02-14
DE60218146T2 (de) 2007-11-22
WO2002080945A3 (en) 2003-06-26
US7122208B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
DE60218146D1 (de) Methoden zur behandlung der entzündungskomponente einer gehirnerkrankung
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
DE602006021485D1 (de) Kontrollierbare vorrichtung und kit zur behandlung von störungen des herzrhythmus-reguliersystems
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
BRPI0307673A2 (pt) métodos de tratar doença vascular.
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE602005017762D1 (de) Methode zur behandlung trockener augen und uveitis
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
WO2007070840A8 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BOLTON, ANTHONY E., TIDESWELL, DERBYSHIRE, GB

Inventor name: MANDEL, ARKADY, NORTH YORK, ONTARIO, CA

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee